Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Tang, Amy H; Hoefer, Richard A; Guye, Mary L; Bear, Harry D.

Afiliação

Tang AH; Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Hoefer RA; School of Systems Biology, George Mason University, Manassas, VA 20110, USA.
Guye ML; Sentara Cancer Network, Sentara Healthcare, Norfolk, VA 23507, USA.
Bear HD; Sentara Cancer Network, Sentara Healthcare, Norfolk, VA 23507, USA.

Cancer Drug Resist ; 5(3): 691-702, 2022.

Article em En | MEDLINE | ID: mdl-36176751

Palavras-chave

EGFR/K-RAS/SIAH pathway activation in TNBC; Triple-negative breast cancer (TNBC); and treatment optimization; chemo-resistance; detection of chemo-resistance; neoadjuvant chemotherapy prognosis; patient risk stratification; precision quantification of therapy efficacy; seven in absentia (SINA) and human homologs of SINA (SIAH) E3 ligase; ubiquitin-mediated proteolysis

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article